BMS收购CAR-T细胞疗法公司2seventy bio

医药魔方
11 Mar

3月10日,CAR-T细胞疗法公司2seventy bio(由bluebird bio拆分而来)宣布被百时美施贵宝(BMS)以每股5.00美元的价格收购其所有流通股份,股本总价值约为2.86亿美元。与2025年3月7日的收盘价(每股2.66美元)相比,这笔交易溢价88%。交易预计将在2025年第二季度完成。根据协议条款,BMS将立即开始一项要约收购,以每股5.00美元的价格以现金交易方式收购...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10